Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Nicotine (as nicotine polacrilex) 2 mg oral gum chewing gum |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Nicotine polacrilex |
Inferred relationship |
Some |
1 |
Product containing precisely nicotine (as nicotine polacrilex) 2 milligram/1 each conventional release oromucosal lozenge (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Nicotine polacrilex |
Inferred relationship |
Some |
1 |
Product containing precisely nicotine (as nicotine polacrilex) 4 milligram/1 chewing gum prolonged-release oral gum (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Nicotine polacrilex |
Inferred relationship |
Some |
1 |
Product containing precisely nicotine (as nicotine polacrilex) 1 milligram/1 each conventional release oromucosal lozenge (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Nicotine polacrilex |
Inferred relationship |
Some |
1 |
Nicotine (as nicotine polacrilex) 4 mg oromucosal lozenge |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Nicotine polacrilex |
Inferred relationship |
Some |
1 |
Nicotine (as nicotine polacrilex) 1.5 mg oromucosal lozenge |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Nicotine polacrilex |
Inferred relationship |
Some |
1 |
Nicotine chewing gum |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Nicotine polacrilex |
Inferred relationship |
Some |
1 |
Nicotine chewing gum |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Nicotine polacrilex |
Inferred relationship |
Some |
1 |